Entinostat: a promising treatment option for patients with advanced breast cancer
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Entinostat is a synthetic benzamide derivative histone deacetylase (HDAC) inhibitor, which potently and selectively inhibits class I and IV HDAC enzymes. This action promotes histone hyperacetylation and transcriptional activation of specific genes, with subsequent inhibition of cell proliferation, terminal differentiation and apoptosis. This oral HDAC inhibitor has been evaluated in Phase I and II trials in patients with advanced malignancies, and is in general well tolerated. Entinostat does not currently have regulatory approval for clinical use; however promising preclinical and clinical data exist in hormone-resistant breast cancer. An ECOG-ACRIN Phase III registration study is ongoing in advanced breast cancer (E2112, NCT02115282) and aims to confirm the overall survival advantage observed with the combination of exemestane and entinostat/placebo in the Phase II setting (ENCORE301 trial). This article provides an overview of the chemistry, pharmacokinetics/pharmacodynamics and available clinical data for entinostat with a focus on advanced breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Entinostat, an oral HDAC inhibitor, induces protein lysine acetylation in preclinical models, which leads to downregulation of estrogen-independent growth factor signaling pathways and normalization of estrogen receptor levels.9,10”
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Deacetylase inhibition promotes the generation and function of regulatory T cells
Tao, R., de Zoeten, E. F., Özkaynak, E., Chen, C., Wang, L., Porrett, P. M., Li, B., Turka, L. A., Olson, E. N., Greene, M. I., et al. (2007) · Nature Medicine · doi:10.1038/nm1652 · Cited by 924
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686
Self-citation
Research works printed but not linked: 1
- 10.1016/S1470-2045(14)71159-3 · DOI · Paper page
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
HDAC Inhibitors in Acute Myeloid Leukemia
San José-Enériz, E., Gimenez-Camino, N., Agirre, X., & Prosper, F. (2019) · Cancers · doi:10.3390/cancers11111794 · Cited by 222
“Entinostat (MS-275) is a synthetic benzamide derivative class I HDACi that potently and selectively leads to cell cycle arrest and hyperacetylation of histones H3 and H4 [167,193,194].”
BackgroundMolecular hybridization: a powerful tool for multitarget drug discovery
de Sena Murteira Pinheiro, P., Franco, L. S., Montagnoli, T. L., & Fraga, C. A. M. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2322990 · Cited by 204
The Chemical Biology of Reversible Lysine Post-translational Modifications
Wang, Z. A., & Cole, P. A. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.07.002 · Cited by 201
Hellmann, M. D., Jänne, P. A., Opyrchal, M., Hafez, N., Raez, L. E., Gabrilovich, D. I., Wang, F., Trepel, J. B., Lee, M.-J., Yuno, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3305 · Cited by 133
“HDAC inhibition has been demonstrated preclinically to improve immune competency through increased MHC presentation and tumor antigen expression and reduced number and function of immunosuppressive cells (15, 17 – 21), particularly myeloid-derived suppressor cells (MDSC; refs.21 ,22).”
Metadata
- Authors
- Connolly, R. M., Rudek, M. A., & Piekarz, R.
- Affiliations
- Sidney Kimmel Comprehensive Cancer Center,Johns Hopkins School of Medicine, Baltimore, MD, USA
- Johns Hopkins University (US)
- National Institutes of Health (US)
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2017-03-09
- Volume
- 13
- Issue
- 13
- Pages
- 1137-1148
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- PMC
- PMC5618943
- OpenAlex
- W2591958823
- Cited by
- 148
- References
- 66
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 22 · 2023: 22 · 2022: 16 · 2021: 19 · 2020: 15 · 2019: 14 · 2018: 7 · 2017: 3
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Future Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Celgene
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- entinostat, histone deacetylase inhibitors, advanced breast cancer, hormone-resistant breast cancer, histone hyperacetylation, benzamide derivatives, pharmacokinetics, pharmacodynamics, anticancer drug development
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Female, Humans, Neoplasm Staging, Pyridines, Apoptosis, Epigenesis, Genetic, Cell Line, Tumor, Cell Proliferation, Histone Deacetylase Inhibitors, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Entinostat: a promising treatment option for patients with advanced breast cancer. https://app.cochat.ai/papers/10.2217/fon-2016-0526
- The paper
- Connolly, R. M., Rudek, M. A., & Piekarz, R. (2017). Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncology. https://doi.org/10.2217/fon-2016-0526
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.